The treatment of Wilms' tumour: results of the United Kingdom Children's cancer study group (UKCCSG) second Wilms' tumour study.
The aims of the UKW2 study were: (1) to further refine treatment for stage I and II favourable histology (FH) patients; (2) to consolidate the UKW1 results for stage III FH patients; (3) to improve the outlook for patients with inoperable primary tumours and those patients with stage IV and unfavourable histology disease. Treatment consisted of primary nephrectomy, wherever possible, followed by chemotherapy and radiotherapy, as dictated by stage and histology. Treatment was refined successfully for stage I and II FH patients. The 4-year event-free survival for these two groups was 94% and 91%, respectively. Stage III FH patients had a 4-year event free survival of 84%. The outlook for patients with clear cell sarcoma of the kidney is as good as for patients with favourable histology, whilst that for patients with anaplastic or rhabdoid variants remains poor. The outlook for the majority of children with Wilms' tumour is now excellent.
Mitchell
C
C
Paediatric Oncology, Oxford Radcliffe Hospital, Oxford, OX 9DU, UK.
Jones
P M
PM
Kelsey
A
A
Vujanic
G M
GM
Marsden
B
B
Shannon
R
R
Gornall
P
P
Owens
C
C
Taylor
R
R
Imeson
J
J
Middleton
H
H
Pritchard
J
J
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery*; D008297:Male; D018335:Rhabdoid Tumor / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D018227:Sarcoma, Clear Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use; D009396:Wilms Tumor / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery*
D014750:Vincristine